NR1H3 and fatty liver disease: Although SH42 treatment largely increased plasma desmosterol levels also in LXRα‐deficient mice (+80%, Fig EV3E), it failed to improve hepatic steatosis (Fig 4A) as evidenced by an unchanged steatosis score (Fig 4B) and similar lipid‐positive areas stained by Oil Red O in SH42 treated mice compared with control (Fig 4A and C).